BioCentury | Oct 3, 2018
Company News

Management tracks: ARM, Rewind, Exscientia

The Alliance for Regenerative Medicine, an advocacy organization for regenerative medicines including cell and gene therapies, appointed Matthew Patterson as chairman for 2019. The group also named Emile Nuwaysir as vice chairman, Amy Butler as...
BioCentury | Jan 5, 2018
Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.1 million) on Jan. 4 in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU...
BioCentury | Jan 4, 2018
Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.2 million) in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for...
Items per page:
1 - 3 of 3
BioCentury | Oct 3, 2018
Company News

Management tracks: ARM, Rewind, Exscientia

The Alliance for Regenerative Medicine, an advocacy organization for regenerative medicines including cell and gene therapies, appointed Matthew Patterson as chairman for 2019. The group also named Emile Nuwaysir as vice chairman, Amy Butler as...
BioCentury | Jan 5, 2018
Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.1 million) on Jan. 4 in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU...
BioCentury | Jan 4, 2018
Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.2 million) in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for...
Items per page:
1 - 3 of 3